Ding D - Search Results

1

Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China.

Liao M, Jiang Q, Hu H, Han J, She L, Yao L, Ding D, Huang J. Liao M, et al. Among authors: ding d. J Med Econ. 2019 Jun;22(6):584-592. doi: 10.1080/13696998.2019.1588125. Epub 2019 Mar 20. J Med Econ. 2019. PMID: 30808230 Free article. Clinical Trial.

2

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.

She L, Hu H, Liao M, Xia X, Shi Y, Yao L, Ding D, Zhu Y, Zeng S, Shen L, Huang J, Carbone DP. She L, et al. Among authors: ding d. Lung Cancer. 2019 Dec;138:88-94. doi: 10.1016/j.lungcan.2019.10.017. Epub 2019 Oct 16. Lung Cancer. 2019. PMID: 31655368

3

Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.

Ding D, Hu H, Liao M, Shi Y, She L, Yao L, Zhu Y, Zeng S, Huang J. Ding D, et al. Adv Ther. 2020 May;37(5):2116-2126. doi: 10.1007/s12325-020-01292-3. Epub 2020 Mar 19. Adv Ther. 2020. PMID: 32193809

4

Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.

Ding D, Hu H, Shi Y, She L, Yao L, Zhu Y, Zeng S, Shen L, Huang J. Ding D, et al. Oncologist. 2021 Feb;26(2):e290-e297. doi: 10.1002/ONCO.13522. Epub 2020 Sep 28. Oncologist. 2021. PMID: 32918790 Free PMC article.

5

Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer.

Hu H, She L, Liao M, Shi Y, Yao L, Ding D, Zhu Y, Zeng S, Carbone DP, Huang J. Hu H, et al. Among authors: ding d. Front Oncol. 2020 Sep 8;10:1649. doi: 10.3389/fonc.2020.01649. eCollection 2020. Front Oncol. 2020. PMID: 33014826 Free PMC article.

6

Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.

Li S, Hu H, Ding D, Zhu Y, Huang J. Li S, et al. Among authors: ding d. Adv Ther. 2021 Mar;38(3):1650-1659. doi: 10.1007/s12325-021-01627-8. Epub 2021 Feb 10. Adv Ther. 2021. PMID: 33569738

7

Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.

Ding D, Hu H, Li S, Zhu Y, Shi Y, Liao M, Liu J, Tian X, Liu A, Huang J. Ding D, et al. J Natl Compr Canc Netw. 2021 Aug 4;19(10):1141-1147. doi: 10.6004/jnccn.2020.7796. J Natl Compr Canc Netw. 2021. PMID: 34348237

8

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis.

Zhu Y, Hu H, Ding D, Li S, Liao M, Shi Y, Huang J. Zhu Y, et al. Among authors: ding d. Cost Eff Resour Alloc. 2021 Dec 4;19(1):77. doi: 10.1186/s12962-021-00329-w. Cost Eff Resour Alloc. 2021. PMID: 34863203 Free PMC article.

9

Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis.

Zhu Y, Liu K, Ding D, Zhou Y, Peng L. Zhu Y, et al. Among authors: ding d. Adv Ther. 2022 Jun;39(6):2614-2629. doi: 10.1007/s12325-022-02101-9. Epub 2022 Apr 8. Adv Ther. 2022. PMID: 35394255

10

First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis.

Zhu Y, Liu K, Ding D, Peng L. Zhu Y, et al. Among authors: ding d. Clin Genitourin Cancer. 2023 Jun;21(3):417.e1-417.e10. doi: 10.1016/j.clgc.2022.11.014. Epub 2022 Nov 25. Clin Genitourin Cancer. 2023. PMID: 36529626 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,112 results

Search Page

Filters